| 1: AJNR
Am J Neuroradiol. 2006 Jun;27(6):1355-6. |
|
-
CNS Clostridium perfringens Infection: A Rare
Complication of Preoperative Embolization of Meningioma.
Yen PS, Lin CC, Lee CC, Harnod T, Loh TW,
Hsu YH.
Departments of Radiology, Buddhist Tzu Chi General Hospital, Hualien,
Taiwan.
SUMMARY: Gas gangrene is a severe form of gangrene (tissue death) that
usually is caused by Clostridium perfringens. It generally occurs at the
site of trauma or a recent surgical wound. We report the case of a
45-year-old woman with sphenoid-ridged meningioma who received preoperative
transarterial embolization with polyvinyl alcohol. The patient later
developed an intratumoral C perfringens infection and died despite intensive
medical care. The case represents an extremely rare complication following
transarterial embolization of meningioma.
PMID: 16775296 [PubMed - in process]
-
| 2: AJNR
Am J Neuroradiol. 2006 Jun;27(6):1275-82. |
|
-
Restored activation of primary motor area from motor
reorganization and improved motor function after brain tumor resection.
Shinoura N, Suzuki Y, Yamada R, Kodama T, Takahashi
M, Yagi K.
Department of Neurosurgery, Komagome Metropolitan Hospital, Tokyo, Japan.
BACKGROUND AND PURPOSE: Reorganization of brain function may result in
preservation of motor function in patients with brain tumors. The goal of
the present study was to investigate whether function of the primary motor
area (M1) was restored and whether motor function improved after brain tumor
resection. METHODS: Five patients with metastatic brain tumors located
within or near M1 underwent awake surgery with intraoperative cortical
mapping and continuous task monitoring. Preoperative and postoperative
functional MR imaging (fMRI) was performed during hand clenching, and
diffusion tensor imaging (DTI) was performed in 1 case to further
characterize the area activated in fMRI. RESULTS: Preoperative fMRI
performed during hand clenching demonstrated reorganization of motor
function. In patients with severe paresis (cases 3, 4, and 5), clenching of
the affected hand induced a large blood oxygen level-dependent response in
the right hemisphere, mainly in the anterior temporal lobe, despite the
location site of the tumor. Postoperative fMRI during hand clenching
demonstrated activation of the contralateral M1. Furthermore, in case 5, DTI
detected tracts, possibly the inferior longitudinal fasciculus, arising from
anterior temporal activated area as well as tracts connecting the premotor
and M1 activated area. This patient demonstrated mirror movement of the hand
during the course of motor function recovery. CONCLUSIONS: Tumor resection
resulted in restoration of M1 function and improved motor function in
patients with preoperative reorganization of M1 function. Furthermore, the
preoperative reorganization of motor function in cases with severe paresis
may be related to changes in the right hemisphere, including the temporal
lobe.
PMID: 16775279 [PubMed - in process]
-
| 3: AJNR
Am J Neuroradiol. 2006 Jun;27(6):1258-71. |
|
-
White matter reorganization after surgical resection of
brain tumors and vascular malformations.
Lazar M, Alexander AL, Thottakara PJ, Badie B, Field
AS.
Laboratory for Brain Imaging and Behavior, University of Wisconsin, Madison,
Wis.
BACKGROUND AND PURPOSE: Diffusion tensor imaging (DTI) and white matter
tractography (WMT) are promising techniques for estimating the course,
extent, and connectivity patterns of the white matter (WM) structures in the
human brain. In this study, DTI and WMT were used to evaluate WM tract
reorganization after the surgical resection of brain tumors and vascular
malformations. METHODS: Pre- and postoperative DTI data were obtained in 6
patients undergoing surgical resection of brain lesions. WMT using a tensor
deflection algorithm was used to reconstruct WM tracts adjacent to the
lesions. Reconstructed tracts included corticospinal tracts, the corona
radiata, superior longitudinal and inferior fronto-occipital fasciculi,
cingulum bundles, and the corpus callosum. RESULTS: WMT revealed a series of
tract alteration patterns including deviation, deformation, infiltration,
and apparent tract interruption. In general, the organization of WM tracts
appeared more similar to normal anatomy after resection, with either
disappearance or reduction of the deviation, deformation, or infiltration
present preoperatively. In patients whose lesions were associated with
corticospinal tract involvement, the WMT reconstructions showed that the
tract was preserved during surgery and improved in position and appearance,
and this finding correlated with improvement or preservation of motor
function as determined by clinical assessment. CONCLUSION: WMT is useful for
appreciating the complex relationships between specific WM structures and
the anatomic distortions created by brain lesions. Further studies with
intraoperative correlation are necessary to confirm these initial findings
and to determine WMT utility for presurgical planning and evaluation of
surgical treatments.
PMID: 16775277 [PubMed - in process]
-
| 4: Ann Neurol. 2006
May;59(5):9A-10A. |
|
-
Comment on:
- Ann Neurol. 2006 May;59(5):755-62.
Low-grade central nervous system lymphoma: clarity
through a hazy lens.
Hauser SL.
Publication Types:
PMID: 16634011 [PubMed - indexed for MEDLINE]
-
| 5: Ann Neurol. 2006
May;59(5):755-62. |
|
-
Comment in:
- Ann Neurol. 2006 May;59(5):9A-10A.
International study on low-grade primary central nervous
system lymphoma.
Jahnke K, Korfel A, O'Neill BP, Blay JY, Abrey
LE, Martus P, Poortmans PM, Shenkier TN, Batchelor
TT, Neuwelt EA, Raizer JJ, Schiff D, Pels H,
Herrlinger U, Stein H, Thiel E.
Department of Hematology, Charite-Universitatsmedizin Berlin, Campus
Benjamin Franklin, Berlin, Germany. kristophe.jahnke@charite.de
OBJECTIVE: The aim of this study was to characterize the clinical
presentation, course, and outcome of low-grade primary central nervous
system lymphoma. METHODS: Cases were assessed in a retrospective series
collected from 18 cancer centers in 5 countries. RESULTS: Forty patients (18
men, 22 women; median age, 60 years [range, 19-78]) were identified.
Involvement of a cerebral hemisphere or deeper brain structures was seen in
37 patients, only leptomeningeal involvement in 2 patients, and spinal cord
disease in 1 patient. Chemotherapy/radiotherapy was conducted in 15
patients, radiotherapy alone in 12, chemotherapy alone in 10, and tumor
resection alone in 2, whereas 1 patient received no treatment. The median
progression-free, disease-specific, and overall survival were 61.5 (range,
0-204), 130 (range, 1-204), and 79 (range, 1-204) months, respectively. Only
age 60 years or older was associated with shorter progression-free (p =
0.009), disease-specific (p = 0.015), and overall survival (p = 0.001) in
multivariate analysis. INTERPRETATION: Low-grade primary central nervous
system lymphoma differs from the high-grade subtype in its pathological,
clinical, and radiological features. It has a better long-term outcome than
primary central nervous system lymphoma in general with age 60 years or
older adversely affecting survival.
Publication Types:
PMID: 16586496 [PubMed - indexed for MEDLINE]
-
| 6: Arch Neurol.
2006 Jun;63(6):906-7. |
|
-
Intracerebral amyloidoma can mimic high-grade glioma on
magnetic resonance imaging and spectroscopy.
Ragel BT, Blumenthal DT, Browd SR, Salzman KL, Jensen
RL.
PMID: 16769875 [PubMed - in process]
-
| 7: Arch
Pathol Lab Med. 2006 Jun;130(6):e96-9. |
|
-
A 65-year-old woman with a left occipital lobe tumor.
Diffuse large B-Cell, primary central nervous system lymphoma.
Nagel SJ, Prayson RA, Weil RJ.
Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, Ohio
44195, USA. nagels@ccf.org
Publication Types:
PMID: 16740056 [PubMed - indexed for MEDLINE]
-
| 8: Arch
Pathol Lab Med. 2006 Jun;130(6):886-9. |
|
-
Cystic tumor of the cerebellum with megaloblastic
erythropoiesis. Hemangioblastoma with megaloblastic hematopoiesis.
Svensson AM, Pang Y, Moore NJ, Tindle BH.
Department of Pathology and Laboratory Medicine, University of Vermont,
Fletcher Allen Health Care, Burlington, VT 05401, USA. Annika.Svensson@uvm.edu
Publication Types:
PMID: 16740048 [PubMed - indexed for MEDLINE]
-
| 9: Br J Cancer.
2006 Jun 19;94(12):1777-84. |
|
-
Efaproxiral red blood cell concentration predicts
efficacy in patients with brain metastases.
Stea B, Shaw E, Pinter T, Hackman J, Craig M,
May J, Steffen RP, Suh JH.
1Department of Radiation Oncology, The University of Arizona Health Sciences
Center, 1501 North Campbell Avenue, Tucson, AZ 85724, USA.
Efaproxiral (Efaproxyntrade mark, RSR13), a synthetic allosteric modifier of
haemoglobin (Hb), decreases Hb-oxygen (O(2)) binding affinity and enhances
oxygenation of hypoxic tumours during radiation therapy. This analysis
evaluated the Phase 3, Radiation Enhancing Allosteric Compound for Hypoxic
Brain Metastases; RT-009 (REACH) study efficacy results in relation to
efaproxiral exposure (efaproxiral red blood cell concentration (E-RBC) and
number of doses). Recursive partitioning analysis Class I or II patients
with brain metastases from solid tumours received standard whole-brain
radiation therapy (3 Gy/fraction x 10 days), plus supplemental O(2) (4
l/min), either with efaproxiral (75 or 100 mg/kg daily) or without
(control). Efaproxiral red blood cell concentrations were linearly
extrapolated to all efaproxiral doses received. Three patient populations
were analysed: (1) all eligible, (2) non-small-cell lung cancer (NSCLC) as
primary cancer, and (3) breast cancer primary. Efficacy endpoints were
survival and response rate. Brain metastases patients achieving sufficient
E-RBC (>/=483 mug/ml) and receiving at least seven of 10 efaproxiral
doses were most likely to experience survival and response benefits.
Patients with breast cancer primary tumours generally achieved the target
efaproxiral exposure and therefore gained greater benefit from efaproxiral
treatment than NSCLC patients. This analysis defined the efaproxiral
concentration-dependence in survival and response rate improvement, and
provided a clearer understanding of efaproxiral dosing requirements.British
Journal of Cancer (2006) 94, 1777-1784. doi:10.1038/sj.bjc.6603169
www.bjcancer.com.
PMID: 16773073 [PubMed - in process]>>>
-
| 10: Cancer Res. 2006
Jun 15;66(12):6457. |
|
-
Glioma, melatonin, and radiotherapy.
Wion D, Berger F, Wion-Barbot N.
Institut National de la Sante et de la Recherche Medicale U318 UJFG, CHU
Michallon, Grenoble, France.
PMID: 16778225 [PubMed - in process]
-
| 11: Clin
Cancer Res. 2006 Jun 15;12(12):3843-3850. |
|
-
Local Targeting of Malignant Gliomas by the Diffusible
Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric
Acid-4,7,10-Triacetic Acid-Substance P.
Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari
A, Hofer S, Kretzschmar M, Tolnay M, Apostolidis
C, Waser B, Arnold M, Mueller-Brand J, Maecke HR,
Reubi JC, Merlo A.
Authors' Affiliations: Clinic and Institute of Nuclear Medicine, Division of
Radiological Chemistry, Neurosurgical Clinic, Molecular Neuro-Oncology
Laboratory of the Department of Surgery and Research, Neuroradiology, and
Neuropathology, University Hospitals, Basel, Switzerland.
PURPOSE: Malignant glial brain tumors consistently overexpress neurokinin
type 1 receptors. In classic seed-based brachytherapy, one to several rigid
(125)I seeds are inserted, mainly for the treatment of small low-grade
gliomas. The complex geometry of rapidly proliferating high-grade gliomas
requires a diffusible system targeting tumor-associated surface structures
to saturate the tumor, including its margins. EXPERIMENTAL DESIGN: We
developed a new targeting vector by conjugating the chelator
1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid to
Arg(1) of substance P, generating a radiopharmaceutical with a molecular
weight of 1,806 Da and an IC(50) of 0.88 +/- 0.34 nmol/L. Cell biological
studies were done with glioblastoma cell lines. neurokinin type-1 receptor
(NK1R) autoradiography was done with 58 tumor biopsies. For labeling, (90)Y
was mostly used. To reduce the "cross-fire effect" in critically
located tumors, (177)Lut and (213)Bi were used instead. In a pilot study, we
assessed feasibility, biodistribution, and early and long-term toxicity
following i.t. injection of radiolabeled
1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid
substance P in 14 glioblastoma and six glioma patients of WHO grades 2 to 3.
RESULTS: Autoradiography disclosed overexpression of NK1R in 55 of 58
gliomas of WHO grades 2 to 4. Internalization of the peptidic vector was
found to be specific. Clinically, the radiopharmeutical was distributed
according to tumor geometry. Only transient toxicity was seen as symptomatic
radiogenic edema in one patient (observation period, 7-66 months). Disease
stabilization and/or improved neurologic status was observed in 13 of 20
patients. Secondary resection disclosed widespread radiation necrosis with
improved demarcation. CONCLUSIONS: Targeted radiotherapy using diffusible
peptidic vectors represents an innovative strategy for local control of
malignant gliomas, which will be further assessed as a neoadjuvant approach.
PMID: 16778112 [PubMed - as supplied by publisher]>>>
-
| 12: Clin
Cancer Res. 2006 Jun 15;12(12):3792-802. |
|
-
Molecular Targeting and Treatment of EGFRvIII-Positive
Gliomas Using Boronated Monoclonal Antibody L8A4.
Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ,
Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger
ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski
MJ, Fenstermaker RA, Wikstrand CJ.
Authors' Affiliations: Departments of Pathology and Pediatrics and
Children's Research Institute, College of Pharmacy, and School of Public
Health, The Ohio State University, Columbus, Ohio.
PURPOSE: The purpose of the present study was to evaluate a boronated
EGFRvIII-specific monoclonal antibody, L8A4, for boron neutron capture
therapy (BNCT) of the receptor-positive rat glioma, F98(npEGFRvIII).
EXPERIMENTAL DESIGN: A heavily boronated polyamido amine (PAMAM) dendrimer
(BD) was chemically linked to L8A4 by two heterobifunctional reagents, N-succinimidyl
3-(2-pyridyldithio)propionate and N-(k-maleimidoundecanoic acid)hydrazide.
For in vivo studies, F98 wild-type receptor-negative or EGFRvIII human gene-transfected
receptor-positive F98(npEGFRvIII) glioma cells were implanted i.c. into the
brains of Fischer rats. Biodistribution studies were initiated 14 days
later. Animals received [(125)I]BD-L8A4 by either convection enhanced
delivery (CED) or direct i.t. injection and were euthanized 6, 12, 24, or 48
hours later. RESULTS: At 6 hours, equivalent amounts of the bioconjugate
were detected in receptor-positive and receptor-negative tumors, but by 24
hours the amounts retained by receptor-positive gliomas were 60.1% following
CED and 43.7% following i.t. injection compared with 14.6% ID/g by
receptor-negative tumors. Boron concentrations in normal brain, blood,
liver, kidneys, and spleen all were at nondetectable levels (<0.5 mug/g)
at the corresponding times. Based on these favorable biodistribution data,
BNCT studies were initiated at the Massachusetts Institute of Technology
Research Reactor-II. Rats received BD-L8A4 ( approximately 40 mug (10)B/
approximately 750 mug protein) by CED either alone or in combination with
i.v. boronophenylalanine (BPA; 500 mg/kg). BNCT was carried out 24 hours
after administration of the bioconjugate and 2.5 hours after i.v. injection
of BPA for those animals that received both agents. Rats that received
BD-L8A4 by CED in combination with i.v. BPA had a mean +/- SE survival time
of 85.5 +/- 15.5 days with 20% long-term survivors (>6 months) and those
that received BD-L8A4 alone had a mean +/- SE survival time of 70.4 +/- 11.1
days with 10% long-term survivors compared with 40.1 +/- 2.2 days for i.v.
BPA and 30.3 +/- 1.6 and 26.3 +/- 1.1 days for irradiated and untreated
controls, respectively. CONCLUSIONS: These data convincingly show the
therapeutic efficacy of molecular targeting of EGFRvIII using either
boronated monoclonal antibody L8A4 alone or in combination with BPA and
should provide a platform for the future development of combinations of high
and low molecular weight delivery agents for BNCT of brain tumors.
PMID: 16778107 [PubMed - in process]
-
| 13: Int
J Radiat Oncol Biol Phys. 2006 Jun 7; [Epub ahead of print] |
|
-
(11)C-METHIONINE PET improves the target volume
delineation of meningiomas treated with stereotactic fractionated
radiotherapy.
Grosu AL, Weber WA, Astner ST, Adam M, Krause
BG, Schwaiger M, Molls M, Nieder C.
Department ofRadiation Oncology.
PURPOSE: To evaluate the role of (11)C-methionine positron emission
tomography (MET-PET) in target volume delineation for meningiomas and to
determine the interobserver variability. METHODS AND MATERIALS: Two
independent observers performed treatment planning in 10 patients according
to a prospective written protocol. In the first step, they used coregistered
computed tomography (CT) and magnetic resonance imaging (MRI). In the second
step, MET-PET was added to CT/MRI (image fusion based on mutual
information). RESULTS: The correlation between gross tumor volume (GTVs)
delineated by the two observers based on CT/MRI was r = 0.855 (Spearman's
correlation coefficient, p = 0.002) and r = 0.988 (p = 0.000) when
MET-PET/CT/MRI were used. The number of patients with agreement in more then
80% of the outlined volume increased with the availability of MET-PET from 1
in 10 to 5 in 10. The median volume of intersection between the regions
delineated by two observers increased significantly from 69% (from the
composite volume) to 79%, by the addition of MET-PET (p = 0.005). The
information of MET-PET was useful to delineate GTV in the area of cavernous
sinus, orbit, and base of the skull. CONCLUSION: The hypothesis-generating
findings of potential normal tissue sparing and reduced interobserver
variability provide arguments for invasive studies of the correlation
between MET-PET images and histologic tumor extension and for prospective
trials of target volume delineation with CT/MRI/MET-PET image fusion.
PMID: 16765533 [PubMed - as supplied by publisher]>>>
-
| 14: J
Clin Oncol. 2006 Jun 1;24(16):2536-43. |
|
-
Health-related quality of life among child and adolescent
survivors of childhood cancer.
Speechley KN, Barrera M, Shaw AK, Morrison HI, Maunsell
E.
Departments of Pediatrics and Epidemiology and Biostatistics, University of
Western Ontario and Children's Health Research Institute, London, ON,
Canada. kathy.speechley@lhsc.on.ca
PURPOSE: The main objective was to compare parent-reported health-related
quality of life (HRQL) of child and adolescent survivors of childhood cancer
to that of controls who had no history of cancer. METHODS: We assessed HRQL
of 800 child and adolescent survivors younger than 16 years and 923 randomly
selected, age- and sex-matched controls from the general population in a
national multicenter retrospective cohort study using the Child Health
Questionnaire parent report. Participation was 69% among survivors and 57%
among controls. RESULTS: Survivors had means that were consistently lower
than controls on the HRQL physical summary (PH; 49.9 v 55.3; P <.005),
psychosocial summary (PS; 49.4 v 52.6; P < .005), and all but one of the
eight subscale scores. Clinically important survivor-control differences in
means on PH were found for survivors of CNS tumors, bone tumors, lymphoma,
leukemia, soft tissue sarcoma and Wilms' tumor (differences: -8.7, -7.0,
-6.3, -5.4, -4.4, -3.8/100, respectively); on PS, survivors of CNS tumors
were most compromised (-6.1/100). Survivor-control differences in both PH
and PS were also large for survivors treated with radiation only (-5.8 and
-11.9/100, respectively), or radiation combined with surgery (-6.6 and
-5.9/100, respectively), or radiation combined with both surgery and
chemotherapy (-7.8 and -5.1/100, respectively). Cranial radiation was
associated with the most compromised HRQL. CONCLUSION: According to parents,
HRQL for survivors was somewhat poorer, overall, than for controls.
Survivors of CNS tumors, lymphoma, and leukemia and those patients treated
with cranial radiation were reported to have poorest HRQL. These findings
support development of guidelines for levels of follow-up care for
particular groups of survivors.
PMID: 16735706 [PubMed - indexed for MEDLINE]>>>
-
| 15: J
Clin Oncol. 2006 Jun 1;24(16):2417-9. |
|
-
Should cervical cancer be an acquired immunodeficiency
syndrome-defining cancer?
Bower M, Mazhar D, Stebbing J.
Department of Oncology, Chelsea and Westminster Hospital, London, United
Kingdom.
PMID: 16735700 [PubMed - indexed for MEDLINE]
-
| 16: J
Clin Oncol. 2006 Jun 1;24(16):e28-9. |
|
-
Erlotinib induced skin rash spares skin in previous
radiotherapy field.
Mitra SS, Simcock R.
Publication Types:
PMID: 16735697 [PubMed - indexed for MEDLINE]
-
| 17: J Neurooncol.
2006 Jun 14; [Epub ahead of print] |
|
-
Primary spinal yolk sac tumor with brain metastasis: case
report and review of the literature.
Kan P, Gottfried ON, Blumenthal DT, Liu JK, Salzman
KL, Townsend J, Jensen RL.
Department of Neurosurgery, University of Utah, Salt Lake City, Utah, USA.
OBJECT: Central nervous system primary germ cell tumors are typically pineal
or suprasellar. Primary germ cell tumors of the spinal axis are very rare,
with only a few case reports of germinomas and teratomas described in the
literature. METHODS: We present the unique case of a 25-year-old woman with
an intradural, extramedullary primary yolk sac tumor (YST) at and below the
level of the conus medullaris. The patient was treated with a subtotal
resection and within a month had rapid regrowth of her YST. She was
subsequently treated with four cycles of chemotherapy (intravenous cisplatin
and etoposide), 40-Gy fractionated focal external beam radiation to the
spine, and consolidation with four additional cycles of chemotherapy
(intravenous carboplatin, vinblastine, etoposide, and bleomycin). Despite an
initial reduction in tumor size and clinical improvement in her neurologic
exam, she re-presented a year after surgery with gross enlargement of her
spinal tumor and CSF dissemination with metastasis to her brain. Despite
further chemotherapy and radiotherapy, the patient died from her
disseminated YST. CONCLUSIONS: This case demonstrates that primary YSTs may
occur in the spine, and like their intracranial counterparts, are associated
with poor prognosis and dissemination through the neuroaxis. When feasible
(no evidence of CSF dissemination, metastasis, or multifocal disease),
optimal treatment includes as extensive resection of tumor as possible
followed by adjuvant chemotherapy and radiation. The authors review the
available literature on the treatment of intracranial malignant germ cell
tumors, extrapolated to apply to the much rarer spinal lesions.
PMID: 16773223 [PubMed - as supplied by publisher]>>>
-
| 18: J Neurooncol.
2006 Jun 14; [Epub ahead of print] |
|
-
Metabolic Manipulation of Glioblastoma in Vivo by
Retrograde Microdialysis of L-2, 4 Diaminobutyric Acid (DAB).
Bergenheim AT, Roslin M, Ungerstedt U, Waldenstrom A,
Henriksson R, Ronquist G.
Department of Neurosurgery, Umea University Hospital, SE 901 85, Umea,
Sweden, tommy.bergenheim@neuro.umu.se.
OBJECTIVES: To study the metabolic effects in vivo of L-2, 4 diaminobutyric
acid (DAB) administered by retrograde microdialysis in glioblastoma and to
evaluate the feasibility of the technique. METHODS: In 10 patients with
glioblastoma, a stereotactic biopsy was performed followed by implantation
of microdialysis catheters. One or two catheters were implanted in tumor
tissue and two reference catheters were implanted in normal brain tissue and
subcutaneous abdominal tissue, respectively. Tumor catheters were perfused
with 80 or 120 mmol/l DAB and reference catheters were perfused with a
Ringer solution, all with a flow rate of 2.0 microl/min. Treatment was given
for at mean 9.1 (5-19) days. RESULTS: The treatment was well tolerated by
the patients with the exception of two patients in whom a transient brain
edema appeared. No complications related to the technique were encountered.
During treatment, an increase in the extracellular amino acids alanine,
glycine, glutamate, aspartate, serine, threonine, and taurine was found
demonstrating a significant influence on the intracellular pool of free
amino acids induced by DAB. No change in glucose metabolism or glycerol was
evident. The metabolism in normal brain was unaffected during treatment.
CONCLUSIONS: Retrograde microdialysis is a feasible method for intracerebral
administration of drugs to tumor tissue in patients with glioblastoma. We
found it possible to deliver DAB to glioblastoma tumors in fully mobilized
patients and to assess the metabolic effects induced by the treatment. The
changes in extracellular amino acids were in concordance to what was
expected from in vitro studies. Elevation of glutamate and taurine may be
regarded as markers for an induced cellular toxicity while the unchanged
level of glycerol may indicate no direct effects on phospholipase activity
and membrane phospholipid composition. The effects were restricted to the
tumor compartment. Although an improved survival could possibly be suspected
no dramatic effect on outcome could be detected. However, the series was
small and, most probably, the time for treatment was too short.
PMID: 16773220 [PubMed - as supplied by publisher]>>>
-
| 19: J Neurooncol.
2006 Jun 14; [Epub ahead of print] |
|
-
S100A13, a new marker of angiogenesis in human astrocytic
gliomas.
Landriscina M, Schinzari G, Di Leonardo G, Quirino M,
Cassano A, D'Argento E, Lauriola L, Scerrati M, Prudovsky
I, Barone C.
Clinical Oncology Unit, Department of Medical Sciences, University of Foggia,
Foggia, Italy.
S100 proteins are Ca(2+)-binding polypeptides involved in the tumourigenesis
of several human neoplasms. S100A13 is a key regulator of the
stress-dependent release of FGF1, the prototype of the FGF protein family
involved in angiogenesis. Indeed, S100A13 is a copper binding protein able
to enhance the export of FGF1 in response to stress in vitro and to induce
the formation of a multiprotein aggregate responsible for FGF1 release. We
investigated the expression of S100A13 in human astrocytic gliomas in
relation to tumour grading and vascularization. A series of 26 astrocytic
gliomas was studied to evaluate microvessel density and to assess FGF1,
S100A13 and VEGF-A expression. FGF1 was equally expressed in the vast
majority of tumours, whereas S100A13 and VEGF-A were significantly
up-regulated in high-grade vascularized gliomas. Moreover, both S100A13 and
VEGF-A expression significantly correlated with microvessel density and
tumour grading. These data suggest that the up-regulation of S100A13 and
VEGF-A expression correlates with the activation of angiogenesis in
high-grade human astrocytic gliomas.
PMID: 16773219 [PubMed - as supplied by publisher]>>>
-
| 20: J Neurooncol.
2006 Jun 14; [Epub ahead of print] |
|
-
Increased Expression of Thymidylate Synthetase (TS),
Ubiquitin Specific Protease 10 (USP10) and Survivin is Associated with Poor
Survival in Glioblastoma Multiforme (GBM).
Grunda JM, Nabors LB, Palmer CA, Chhieng DC, Steg
A, Mikkelsen T, Diasio RB, Zhang K, Allison D,
Grizzle WE, Wang W, Gillespie GY, Johnson MR.
Departments of Pharmacology and Toxicology, Division of Clinical
Pharmacology, University of Alabama at Birmingham, Birmingham, AL, 35294,
USA.
BACKGROUND: The limited success of empirically designed treatment paradigms
for patients diagnosed with glioblastoma multiforme (GBM) emphasizes the
need for rationally designed treatment strategies based on the molecular
profile of tumor samples and their correlation to clinical parameters.
METHODS: In the current study, we utilize a novel real-time quantitative low
density array (RTQ-LDA) to identify differentially expressed genes in de
novo GBM tissues obtained from patients with distinctly different clinical
outcomes. Total RNA was isolated from a cohort of 21 GBM specimens obtained
from patients with either good (long-term survival (LTS) >36 months post
surgery, n = 8) or poor (died of the disease (DOD) <24 months post
surgery, n = 13) prognosis. Non-neoplastic brain tissue (n = 5) was obtained
from patients who underwent surgery for refractory epilepsy. Demographic
data was assessed for correlation with survival using Cox proportional
hazards models. Sufficient RNA was available to use RTQ-LDA to quantify the
expression of 93 independent genes in 5 LTS, 4 DOD, and 5 non-neoplastic
brain samples. The eight differentially expressed genes identified by
RTQ-LDA in LTS versus DOD (P </= 0.050) were subsequently quantified in
all 21 GBM samples by real-time quantitative PCR (RTQ). RESULTS: A
correlation between younger patients and good prognosis was demonstrated (P
</= 0.05). The combination of RTQ-LDA and RTQ identified thymidylate
synthetase (TS), ubiquitin specific protease 10 (USP10), and survivin as
significantly over-expressed (P </= 0.050) in DOD compared to LTS
patients. Ribonucleotide reductase subunit M2 (RRM2) was identified as
tumor-specific, but not associated with survival. CONCLUSIONS: Taken
collectively, TS, USP10, survivin and RRM2 may be useful as prognostic
indicators and/or in the development of rationally designed treatment
protocols.
PMID: 16773218 [PubMed - as supplied by publisher]>>>
-
| 21: J Neurooncol.
2006 Jun 14; [Epub ahead of print] |
|
-
Images in Neuro-Oncology. Selective Invasion of the
Anterior Commissure in Glioblastoma Multiforme.
Yang BP, Das S, Yang CW, Cozzens JW.
Department of Neurosurgery, Evanston Hospital, Northwestern University
Feinberg School of Medicine, 600 N. McClurg Court, 4404A, Chicago, Illinois,
60611, USA, b-yang1@md.northwestern.edu.
PMID: 16773217 [PubMed - as supplied by publisher]
-
| 22: J Neurooncol.
2006 Jun 14; [Epub ahead of print] |
|
-
Intracranial Thermotherapy using Magnetic Nanoparticles
Combined with External Beam Radiotherapy: Results of a Feasibility Study on
Patients with Glioblastoma Multiforme.
Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust
P, Thiesen B, Feussner A, von Deimling A, Waldoefner
N, Felix R, Jordan A.
Department of Neurosurgery, Bundeswehrkrankenhaus, Berlin, Germany,
KlausMaierHauff@bundeswehr.org.
We aimed to evaluate the feasibility and tolerability of the newly developed
thermotherapy using magnetic nanoparticles on recurrent glioblastoma
multiforme. Fourteen patients received 3-dimensional image guided
intratumoral injection of aminosilane coated iron oxide nanoparticles. The
patients were then exposed to an alternating magnetic field to induce
particle heating. The amount of fluid and the spatial distribution of the
depots were planned in advance by means of a specially developed treatment
planning software following magnetic resonance imaging (MRI). The actually
achieved magnetic fluid distribution was measured by computed tomography
(CT), which after matching to pre-operative MRI data enables the calculation
of the expected heat distribution within the tumor in dependence of the
magnetic field strength. Patients received 4-10 (median: 6) thermotherapy
treatments following instillation of 0.1-0.7 ml (median: 0.2) of magnetic
fluid per ml tumor volume and single fractions (2 Gy) of a radiotherapy
series of 16-70 Gy (median: 30). Thermotherapy using magnetic nanoparticles
was tolerated well by all patients with minor or no side effects. Median
maximum intratumoral temperatures of 44.6 degrees C (42.4-49.5 degrees C)
were measured and signs of local tumor control were observed. In conclusion,
deep cranial thermotherapy using magnetic nanoparticles can be safely
applied on glioblastoma multiforme patients.
PMID: 16773216 [PubMed - as supplied by publisher]>>>
-
| 23: J Neurooncol.
2006 Jun 14; [Epub ahead of print] |
|
-
Utilization and Cost of Health Care Services Associated
with Primary Malignant Brain Tumors in the United States.
Kutikova L, Bowman L, Chang S, Long SR, Thornton
DE, Crown WH.
Global Health Outcomes Research, Eli Lilly and Company, Lilly Corporate
Center, DC 1833, Indianapolis, IN, 46285, USA, kutikova_lucie@lilly.com.
OBJECTIVES: To evaluate the economic burden of primary malignant brain
tumors in a commercially insured population in the United States, and to
identify the primary drivers of health care resource use and cost. PATIENTS
AND METHODS: A retrospective cohort analysis was performed using a 1998-2000
database containing inpatient, outpatient, and pharmacy claims for
employees, their dependents, and early retirees of over 50 large US
employers with wide geographic distribution. Patients were followed from
first brain tumor diagnosis until death, termination of health benefits
coverage, or study end. Controls without any cancer diagnosis were matched
at a 3:1 ratio by demographic characteristics and length of follow-up.
RESULTS: Patients with malignant brain tumors (n = 653) had significantly
greater health service utilization and costs for hospitalizations, emergency
room visits, outpatient office visits, laboratory tests, radiology services,
and pharmacy-dispensed drugs (all P < 0.05) than did controls (n = 1959).
Regression-adjusted mean monthly costs were $6364 for brain tumor patients,
compared with $277 for controls (P < 0.0001). The primary cost driver was
inpatient care ($4502 per month). Total costs during the study period were
$49,242 for those with brain tumors and $2790 for controls (P < 0.0001).
CONCLUSION: Patients with malignant brain tumors accrued health care costs
that were 20 times greater than demographically matched control subjects
without cancer. The costs for inpatient services were the primary drivers of
total health resource use. Despite their low incidence, primary malignant
brain tumors produce a substantial burden on the US health care system.
There is a marked need for improved and new approaches to treatment to
reduce the resource use and to offset health care costs associated with this
disease.
PMID: 16773215 [PubMed - as supplied by publisher]>>>
-
| 24: J Neurooncol.
2006 Jun 14; [Epub ahead of print] |
|
-
Lipid Peroxidation and Activity of Some Antioxidant
Enzymes in Patients with Glioblastoma and Astrocytoma.
Wozniak B, Wozniak A, Kasprzak HA, Drewa G, Mila-Kierzenkowska
C, Drewa T, Planutis G.
Department and Clinic of Neurosurgery and Neurotraumatology, Ludwik Rydygier
Medical University, Sklodowska-Curie 9, 85-094, Bydgoszcz, Poland.
The aim of this study was to evaluate the concentration of
malondialdehyde-MDA (one of the lipid peroxidation products)-in blood plasma
and erythrocytes and the activity of superoxide dismutase (SOD) and catalase
(CAT) in red blood cells of patients with a primary brain tumour. The study
was performed on 24 patients with a brain tumour (9 with glioblastoma and 15
with asrocytoma) treated in the Department and Clinic of Neurosurgery and
Neurotraumatology at Ludwik Rydygier Medical University in Bydgoszcz. The
control group consisted of 20 healthy volunteers. A statistically
significant higher MDA concentration in erythrocytes and blood plasma and a
higher activity of SOD or CAT in erythrocytes was shown in patients with a
brain tumour as compared to the control group. Neither the histological type
of tumour nor surgery has an effect on the tested biochemical parameters.
PMID: 16773213 [PubMed - as supplied by publisher]
-
| 25: J
Neuropathol Exp Neurol. 2006 May;65(5):516-27. |
|
-
Metalloproteinase disintegrins ADAM8 and ADAM19 are
highly regulated in human primary brain tumors and their expression levels
and activities are associated with invasiveness.
Wildeboer D, Naus S, Amy Sang QX, Bartsch JW, Pagenstecher
A.
Developmental Biology and Molecular Pathology, Bielefeld University,
Bielefeld, Germany.
Patients with primary brain tumors have bleak prognoses and there is an
urgent desire to identify new markers for sensitive diagnosis and new
therapeutic targets for effective treatment. A family of proteins, the
disintegrin and metalloproteinases (ADAMs or adamalysins), are cell surface
and extracellular multidomain proteins implicated in cell-cell signaling,
cell adhesion, and cell migration. Their putative biological and
pathological roles make them candidates for promoting tumor growth and
malignancy. We investigated the expression levels of 12 cerebrally expressed
ADAM genes in human primary brain tumors (astrocytoma WHO grade I-III,
glioblastoma WHO grade IV, oligoastrocytoma WHO grade II and III,
oligodendroglioma WHO grade II and III, ependymoma WHO grade II and III, and
primitive neuroectodermal tumor WHO grade IV) using real-time PCR. The mRNAs
of the five ADAMs 8, 12, 15, 17, and 19 were significantly upregulated. The
ADAM8 and ADAM19 proteins were mainly located in tumor cells and in some
tumors in endothelia of blood vessels. In brain tumor tissue, ADAM8 and
ADAM19 undergo activation by prodomain removal resulting in active
proteases. By using specific peptide substrates for ADAM8 and ADAM19,
respectively, we demonstrated that the proteases exert enhanced proteolytic
activity in those tumor specimens with the highest expression levels. In
addition, expression levels and the protease activities of ADAM8 and ADAM19
correlated with invasive activity of glioma cells, indicating that ADAM8 and
ADAM19 may play a significant role in tumor invasion that may be detrimental
to patients survival.
PMID: 16772875 [PubMed - in process]
-
| 26: J
Neuropathol Exp Neurol. 2006 May;65(5):465-77. |
|
-
Altered cellular distribution and subcellular sorting of
gamma-tubulin in diffuse astrocytic gliomas and human glioblastoma cell
lines.
Katsetos CD, Reddy G, Draberova E, Smejkalova B,
Del Valle L, Ashraf Q, Tadevosyan A, Yelin K, Maraziotis
T, Mishra OP, Mork S, Legido A, Nissanov J, Baas
PW, de Chadarevian JP, Draber P.
Department of Pediatrics, Drexel University College of Medicine, St.
Christopher's Hospital for Children, Philadelphia, Pennsylvania 19134, USA.
Christos.Katsetos@DrexelMed.edu
Centrosome amplification is a pivotal mechanism underlying tumorigenesis but
its role in gliomas is underinvestigated. The present study specifically
examines the expression and distribution of the centrosome-associated
cytoskeletal protein gamma-tubulin in 56 primary diffuse astrocytic gliomas
(grades II-IV) and in 4 human glioblastoma cell lines (U87MG, U118MG,
U138MG, and T98G). Monoclonal anti-peptide antibodies recognizing epitopes
in C-terminal or N-terminal domains of the gamma-tubulin molecule were used
in immunohistochemical, immunofluorescence, and immunoblotting studies. In
tumors in adults (n = 46), varying degrees of localization were detected in
all tumor grades, but immunoreactivity was significantly increased in
high-grade anaplastic astrocytomas and glioblastomas multiforme as compared
to low-grade diffuse astrocytomas (p = 0.0001). A similar trend was noted in
diffuse gliomas in children but the sample of cases was too small as to be
statistically meaningful. Two overlapping patterns of ectopic cellular
localization were identified in both primary tumors and glioblastoma cell
lines: A punctate pattern, in which gamma-tubulin was partially
co-distributed with pericentrin in the pericentriolar region, and a diffuse
pattern, independent of pericentrin staining, denoting a soluble pool of
gamma-tubulin. Cellular gamma-tubulin was detected in both soluble and
insoluble (nocodazole-resistant) fractions of glioblastoma cells. Divergent
localizations of gamma-tubulin and pericentrin suggest a differential
distribution of these 2 centrosome-associated proteins in glioblastoma cell
lines. Our results indicate that overexpression and ectopic cellular
distribution of gamma-tubulin in astrocytic gliomas may be significant in
the context of centrosome protein amplification and may be linked to tumor
progression and anaplastic potential.
PMID: 16772870 [PubMed - in process]
-
| 27: J
Neuropathol Exp Neurol. 2006 May;65(5):445-54. |
|
-
Microarray-based analysis of spinal versus intracranial
meningiomas: different clinical, biological, and genetic characteristics
associated with distinct patterns of gene expression.
Sayagues JM, Tabernero MD, Maillo A, Trelles O, Espinosa
AB, Sarasquete ME, Merino M, Rasillo A, Vera JF,
Santos-Briz A, de Alava E, Garcia-Macias MC, Orfao A.
Servicio General de Citometria, Departamento de Medicina and Centro de
Investigacion del Cancer, Universidad de Salamanca, Salamanca, Spain.
It has long been recognized that spinal meningiomas show particular clinical
and histological features. Here, we compare the clinico-biological
characteristics as well as the genetic abnormalities and patterns of gene
expression of spinal and intracranial meningiomas. Fourteen spinal and 141
intracranial meningioma patients were analyzed at diagnosis. In all tumors,
interphase fluorescence in situ hybridization (iFISH) studies were performed
for the detection of quantitative abnormalities for 11 different
chromosomes. Additionally, microarray analyses were performed on a subgroup
of 18 histologically benign meningiomas (7 spinal and 11 intracranial). Upon
comparison with intracranial tumors, spinal meningiomas showed a marked
predominance of psammomatous and transitional tumors (p = 0.001), together
with a higher proportion of cases displaying a single tumor cell clone by
iFISH (p = 0.004). In 86% of the spinal versus 56% of the intracranial
tumors (p = 0.01), the ancestral tumor cell clone detected showed either
absence of any chromosomal abnormality or monosomy 22/22q- alone. Analysis
of gene expression profiles showed differential expression between spinal
and intracranial meningiomas for a total of 1555 genes, 35 of which allowed
a clear distinction between both tumor types. Most of these 35 genes (n =
30) showed significantly higher expression among spinal tumors and
corresponded to genes involved in signal transduction pathways, which did
not show a significantly different expression according to tumor
histopathology. In summary, we show the occurrence of unique patterns of
genetic abnormalities and gene expression profiles in spinal as compared to
intracranial meningiomas that provide new insights into the molecular
pathways involved in the tumorigenesis and progression of spinal meningiomas,
and could help explain their particular clinical and histological features.
PMID: 16772868 [PubMed - in process]>>>
-
| 28: J Neurosurg.
2006 Jun;104(6):907-12. |
|
Local control of brain metastases by stereotactic
radiosurgery in relation to dose to the tumor margin.
Vogelbaum MA, Angelov L, Lee SY, Li L, Barnett
GH, Suh JH.
Brain Tumor Institute and Departments of Biostatistics, Neurosurgery, and
Radiation Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA. vogelbm@neus.ccf.org
OBJECT: The maximal tolerated dose (MTD) for stereotactic radiosurgery (SRS)
for brain tumors was established by the Radiation Therapy Oncology Group (RTOG)
in protocol 90-05, which defined three dose groups based on the maximal
tumor diameter. The goal in this retrospective study was to determine
whether differences in doses to the margins of brain metastases affect the
ability of SRS to achieve local control. METHODS: Between 1997 and 2003, 202
patients harboring 375 tumors that met study entry criteria underwent SRS
for treatment of one or multiple brain metastases. The median overall
follow-up duration was 10.7 months (range 3-83 months). A dose of 24 Gy to
the tumor margin had a significantly lower risk of local failure than 15 or
18 Gy (p = 0.0005; hazard ratio 0.277, confidence interval [CI]
0.134-0.573), whereas the 15- and 18-Gy groups were not significantly
different from each other (p = 0.82) in this regard. The 1-year local
control rate was 85% (95% CI 78-92%) in tumors treated with 24 Gy, compared
with 49% (CI 30-68%) in tumors treated with 18 Gy and 45% (CI 23-67%) in
tumors treated with 15 Gy. Overall patient survival was independent of dose
to the tumor margin. CONCLUSIONS: Use of the RTOG 90-05 dosing scheme for
brain metastases is associated with a variable local control rate. Tumors
larger than 2 cm are less effectively controlled than smaller lesions, which
can be safely treated with 24 Gy. Prospective evaluations of the
relationship between dose to the tumor margin and local control should be
performed to confirm these observations.
PMID: 16776334 [PubMed - in process]>>>
-
| 29: Neurology. 2006 May
9;66(9):1435-8. |
|
-
MATILDE regimen followed by radiotherapy is an active
strategy against primary CNS lymphomas.
Ferreri AJ, Dell'Oro S, Foppoli M, Bernardi M, Brandes
AA, Tosoni A, Montanari M, Balzarotti M, Spina M,
Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli
G, Baldini L, Ponzoni M, Picozzi P, Caligaris
Cappio F, Reni M.
Medical Oncology Unit, San Raffaele H Scientific Institute, Universita
Vita-Salute San Raffaele, Milan, Italy. ferreri.andres@hsr.it
The authors assessed MATILDE chemotherapy followed by response-tailored
radiation therapy in 41 patients aged 70 years or younger with primary CNS
lymphoma in a Phase II trial. With response rates of 76% after MATILDE and
83% after chemotherapy with or without radiation therapy, this was an active
strategy, particularly in low- to intermediate-risk patients (International
Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the
dose-limiting toxicity, with 9.5% of lethal complications. After a median
follow-up of 49 months, a plateau in the survival curve (5-year overall
survival: 41 +/- 7%) was obtained.
Publication Types:
PMID: 16682682 [PubMed - indexed for MEDLINE]>>>
-
| 30: Neurology. 2006 May
9;66(9):E33-4. |
|
-
Clinical findings of the phakomatoses: von Hippel-Lindau
disease.
Quigg M, Rust RS, Miller JQ.
Department of Neurology, University of Virginia, Charlottesville, VA 22908,
USA. Quigg@virginia.edu
PMID: 16682653 [PubMed - indexed for MEDLINE]
-
| 31: Neurology. 2006 May
9;66(9):E32. |
|
-
Leukoencephalopathy with cerebral calcifications and
cysts.
Brenner C, Del Negro MC, Borigato EM, Miranda RV.
c.brenner@uol.com.br
Publication Types:
PMID: 16682652 [PubMed - indexed for MEDLINE]
-
| 32: Rev Neurol.
2006 Jun 16-30;42(12):735-42. |
|
[Magnetic resonance imaging with spectroscopy, perfusion
and cerebral diffusion in the diagnosis of brain tumours.]
[Article in Spanish]
Fayed-Miguel N, Morales-Ramos H, Modrego-Pardo PJ.
Clinica Quiron Donostia, 20012 San Sebastian, Espana.
AIM. We review three of the most important functional techniques in magnetic
resonance imaging, it means spectroscopy, perfusion and diffusion; we do
emphasize in its applications, particularly in the diagnostic and treatment
of brain tumors. First, we discuss the physical principles and results
interpretation of each technique. After that, we discuss its major
applications. DEVELOPMENT AND CONCLUSIONS. Choline containing compounds
using contralateral creatine and choline for normalization or ipsilateral
N-acetyl-aspartate appeared to correlate best with the degree of tumor
infiltration, regardless o tumor histological grade. Magnetic resonance
spectroscopy imaging (MRSI) seems more accurate than conventional magnetic
resonance imaging (MRI) in defining indistinct tumor boundaries and
quantifying the degree of tumor infiltration. MRSI is the choice of site
within a lesion for biopsy and use in image-guided therapy, including
definition of radiation ports. Angiogenesis, and increased vascular
permeability, are characteristic of cerebral neoplasms; these processes can
be imaged using perfusion MRI. Most commonly, tumor perfusion is measured
using rapid gradient T<sub>2</sub>-weighted imaging during bolus
injection of gadolinium dimeglumine gadopentetate. Care has to be taken to
avoid blood-brain barrier leakage affecting perfusion results.
Pharmacokinetic models are available for estimation of blood-brain
permeability. Cerebral blood volume increases with tumor grade, and maybe
helpful in identifying tumor recurrence, and peri-tumoral edema, and
distinguishing malignant from benign lesions.
PMID: 16775800 [PubMed - in process]>>>
-
| 33: Rev Neurol.
2006 Jun 16-30;42(12):733-4. |
|
[A bleak outlook for brain tumours. The challenge of
cooperative working.]
[Article in Spanish]
Lafuente-Sanchez JV.
Universidad del Pais Vasco. Facultad de Medicina y Odontologia., 48080
Bilbao, Espana.
PMID: 16775799 [PubMed - in process]-
|
Volume 5, Number 25 - 19 June 2006